This invention belongs to the pharmaceutical field, specifically relating to the application of phosphopamine
hydrochloride in the preparation of drugs for treating
preeclampsia. The application of phosphopamine
hydrochloride in the preparation of drugs for treating
preeclampsia involves the phosphopamine
hydrochloride exerting its effect by promoting
trophoblast motility. This effect is achieved by regulating the
lactation modification of α-
actin-4. The phosphopamine hydrochloride salvages
trophoblast functional damage in
preeclampsia by inhibiting
lactation at the ACTN4 K346 site. This invention reveals for the first time that the
lactation modification at the ACTN4
protein K346 site is abnormally elevated in
placental tissue of PE patients. This modification can impair
trophoblast function and drive
disease progression. Phosphopamine hydrochloride can target and inhibit lactation modification at this site, reversing trophoblast functional damage and demonstrating good therapeutic potential.